Gilead Sciences

News

Kymera signs $750m cancer deal with Gilead as Sanofi opts in

Kymera is celebrating the signing of two partnerships, with Gilead taking an option on one molecular glue programme, as Sanofi buys into another.

News

Gilead's twice-yearly PrEP drug is cleared by FDA

Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?

News

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC).

News

Gilead Sciences' chief executive Daniel O'Day

Gilead ups its US investment plans by $11 billion

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US.

News

Women & HIV ambassador, Iris, on a block 'I' in 'HIV'

UK's HIV response is 'failing women'

Women are being overlooked in the UK's HIV response and can face barriers to accessing prevention, testing and care, says a new campaign.

News

Vials on a conveyor belt - pharma manufacturing

Trodelvy-Keytruda pairing hits the spot in breast cancer

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.

Kymera signs $750m cancer deal with Gilead as Sanofi opts in

Gilead's twice-yearly PrEP drug is cleared by FDA

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

Gilead ups its US investment plans by $11 billion

UK's HIV response is 'failing women'

Trodelvy-Keytruda pairing hits the spot in breast cancer

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Gilead Sciences

Editor's Picks